TRIPLET COMBINATION FORMULATIONS AND METHODS FOR TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE

1 .- 40 . (canceled)

41 . A pharmaceutical composition comprising:

ETC-1002;

Ezetimibe;

a statin; and

one or more pharmaceutically acceptable excipients or carriers.

42 . The pharmaceutical composition of claim 41 , wherein the amount of ETC-1002 is 180 or 120 mg.

43 . The pharmaceutical composition of claim 41 , wherein the amount of ETC-1002 is between 40 mg to 90 mg.

44 . The pharmaceutical composition of claim 41 , wherein the amount of Ezetimibe is 10 mg.

45 . The pharmaceutical composition of claim 41 , wherein the amount of the statin is between 1 mg to 80 mg.

46 . The pharmaceutical composition of claim 41 , wherein the statin is selected from the group consisting of: atorvastatin, simvastatin, fluvastatin, rosuvastatin, and pitavastatin.

47 . The pharmaceutical composition of claim 41 , wherein the statin is atorvastatin.

48 . The pharmaceutical composition of claim 47 , wherein the amount of atorvastatin is between 10 and 80 mg.

49 . The pharmaceutical composition of claim 41 , wherein the statin is simvastatin.

50 . The pharmaceutical composition of claim 49 , wherein the amount of simvastatin is between 10 and 40 mg.

51 . The pharmaceutical composition of claim 41 , wherein the statin is fluvastatin.

52 . The pharmaceutical composition of claim 51 , wherein the amount of fluvastatin between 20 and 80 mg.

53 . The pharmaceutical composition of claim 41 , wherein the statin is rosuvastatin.

54 . The pharmaceutical composition of claim 53 , wherein the amount of rosuvastatin is between 5 and 40 mg.

55 . The pharmaceutical composition of claim 41 , wherein the statin is pitavastatin.

56 . The pharmaceutical composition of claim 55 , wherein the amount of pitavastatin is between 1 and 4 mg.

57 .- 61 . (canceled)